As of 2026-10-06 03:13 UTC.Market figures are as the cited sources reported them at that time and may have moved since. This is news, not investment advice.
Goldman Sachs downgraded Carl Zeiss Meditec from Neutral to Sell on 5 October 2026, cutting the stock's price target from €27.00 to €23.00. The revised target reflects approximately 26% downside for the shares.[6][1]